Company profile for MaxCyte

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines. We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our tea...
We are a U.S.-based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines. We provide our patented, high-performance cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology. With our robust delivery platform, our team of scientific experts helps our partners unlock the potential of their products and solve development and commercialization challenges.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
22 Firstfield Road, Suite 110 Gaithersburg, MD 20878
Telephone
Telephone
+1-301-944-1700
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/12/3186804/0/en/MaxCyte-Announces-Planned-CFO-Transition-in-2026.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/12/3186765/0/en/MaxCyte-Reports-Third-Quarter-2025-Financial-Results-and-Reiterates-Full-Year-2025-Revenue-Guidance.html

GLOBENEWSWIRE
12 Nov 2025

https://www.globenewswire.com/news-release/2025/11/05/3181436/0/en/MaxCyte-Reports-Preliminary-Third-Quarter-2025-Financial-Results-and-Reiterates-Full-Year-2025-Revenue-Guidance.html

GLOBENEWSWIRE
05 Nov 2025

https://www.globenewswire.com/news-release/2025/10/08/3163305/0/en/MaxCyte-to-Report-Third-Quarter-2025-Financial-Results-on-November-5-2025.html

GLOBENEWSWIRE
08 Oct 2025

https://www.globenewswire.com/news-release/2025/10/06/3161686/0/en/MaxCyte-Announces-Strategic-Platform-License-Agreement-with-Moonlight-Bio-to-Advance-T-Cell-Therapies-for-Solid-Tumors.html

GLOBENEWSWIRE
06 Oct 2025

https://www.globenewswire.com/news-release/2025/09/22/3154315/0/en/MaxCyte-Announces-Operational-Restructuring-to-Reduce-Costs-and-Accelerate-Path-to-Profitability.html

GLOBENEWSWIRE
22 Sep 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Contact MaxCyte and get a quotation

MaxCyte is a supplier offers 1 products (APIs, Excipients or Intermediates).

Find a price of Raw materials for cell processing, etc.-MaxCyte ExPERTTM GTx Flow Transfection System bulk with JDMF offered by MaxCyte

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty